£64.6 million AIM IPO for Trellus Health

About Trellus Health

Trellus Health is commercialising the provision of digital chronic condition management solutions for health plans and employers that utilise the scientifically validated Gaining Resilience Through Transitions (GRITT™) methodology and a proprietary HIPAA compliant technology platform called TrellusElevate™, to coordinate and deliver personalised care remotely via telemedicine.

The GRITT™ methodology and resilience-driven multidisciplinary care model have been scientifically validated to demonstrate meaningful improvements in patient outcomes and over 85% reduction in emergency department visits and hospitalisations. The Company is initially focused on Inflammatory Bowel Diseases (“IBD”), which include the chronic incurable conditions of Crohn’s Disease and ulcerative colitis, but also considers its approach to have potential utility and demand across many chronic conditions.

Key facts

£28.5 million

raised in an Oversubscribed Placing, Subscription and a Restricted Offer

Proceeds of Fundraise

used for a range of commercialisation purposes, research collaborations and geographic expansion.

£64.6 million

market capitalisation upon Admission

"We are delighted by the strong support shown by institutional and other investors in our IPO and incredibly proud to have reached this important milestone. Our AIM IPO will enable us to scale our business and technology platform in the US and abroad, and in turn inspire hope and significantly improve outcomes for people suffering with chronic conditions."

Monique Fayad

Chief Executive Officer of Trellus Health